Alzheimer's disease (AD) is a mental challenge that occurs in the brain. It is a disease that makes people lose memory or even lack the capacity to lead a healthy lifestyle due to memory loss. It affects people as they get older, especially the ones above 65 years, than the ones with fewer years. The disease can also affect young people aged between forty and fifty years old, in what is known as the younger-onset (DeFina et al., par 9).
Research on the Treatment and the Fight against the Alzheimer's disease
There has been a lot of research done on the causes, treatment, and the preventive measure, in the effort to do away with the Alzheimer's disease. The efforts of the medical practitioners have been great though the cure for the illness has not yet been obtained.
The primary determination of the causes of the disease is challenging, given that the disease is usually associated with other conditions and factors such as the cerebrovascular disease, the delirium depression, Lewy body disease, as well as normal pressure hydrocephalus (NPH).
Researchers have, however, been able to do intense research on the interventional measures that can be applied to either, subdue the disease or even do away with it. The actions that have been adopted are based on the underlying understanding of the medical field and the causes of the disease. The research has been done on the medical areas such as the neurophysiological field, the pharmaceutical field, the nutraceutical, cognitive and the general physical health sector.
The research has however been intensified in for areas that touch in the pharmaceuticals industry, and whose main aim is to antithesis the neural corrosion, whose origin is the Alzheimer disease. The other reason is to stop the advancement of illness in the brain.
The research aims at achieving a standard that aims at establishing strong disease-modifying treatments. The study aims at using a combination of drugs, whose primary purpose is to suppress the factors associated with the advancement of the disease, such as the Aβ deposits, insulin resistance, immune dysregulation, and inflammation among other factors.
The research has been a success, based on the results that have been obtained such as the phase II clinical trial of IVIG. The experiment was done on an immunotherapy agent, which was found to have the ability to alleviate the intellect and the operational ability of the patient diagnosed with the AD, for not less than three years.
There are high hopes that are based on the general research on the Alpha GPC, the choline, Huperzine A, and phosphatidylserine, which an active promise on the nutraceutical agents, that help in the development of the cognitive performance, and even subduing the cognitive deterioration.
The patients with the Alzheimer's disease have a lot of hope that a cure or even a preventive mechanism is on the way to make their lives better. The improvement of medical foods, such as Souvenaid, Axona, and CerefolinNAC, which help in the improvement of the mental status, is a great achievement for the patients suffering from the disease.
The general use of the translational models has been of great help in the identification of all the factors leading to the neuropathogenetic advancement of the AD. The use of translational models aims at the reduction of the toxic builds up in the cells, as well as prevention of the cell loss through the apoptosis process.
Conclusion
The research on the fight against the AD has been a success, and it gives hope to the people suffering from the disease. All the patients can have hope, that soon; a medical treatment might be put in place that looks into all matters concerning their health issues.
Works cited
DeFina Philip A., Moser Rosemarie Scolaro, Glenn Megan, Lichtenstein Jonathan D., and Fellows Jonathan. “Alzheimer's Disease Clinical and Research Update for Health Care Practitioners.” Journal of Aging Research, Volume 2013 (2013), Article ID 207178, nine pages (http://dx.doi.org/10.1155/2013/207178)
